INTRODUCTION {#sec0005}
============

The prognosis of patients with advanced urothelial carcinoma (UC) is frustratingly poor, owing to the negative results of several clinical trials that were aimed to improve the achievable outcomes with standard chemotherapy \[[@ref001]\]. New advances with the use of immune checkpoint inhibitors are being made in this disease and atezolizumab, a monoclonal antibody targeting the programmed death-ligand 1 (PD-L1), was granted conditional approval in the post-platinum metastatic setting by the U.S. Food and Drug Administration (FDA) \[[@ref002]\]. Similarly, promising results from another study with a PD-L1 antibody, durvalumab, have been presented \[[@ref003]\], recognizing the fact that metastatic UC represents an area of enormous unmet medical need. Waiting for the results of clinical trials of immunotherapy in earlier disease stages, improvements in the administration of standard chemotherapy options as well as novel prognostic factors are warranted in the first-line setting. Thus far, the greatest improvement in the context of standard therapy would be to provide clinicians with tools to early change ineffective treatments and anticipate new drugs in these patients.

Circulating tumor cells (CTC) represent a useful blood-borne biomarker to monitor the disease course and their clinical validity has been well acknowledged in genitourinary cancers, especially in castration-resistant prostate cancer \[[@ref004]\]. Both molecular and immunological approaches have been used to detect or enumerate CTCs in patients with superficial or metastatic UC. Urothelial and tumor-specific markers, such as cytokeratin-18, -19 and -20, uroplakin II, epidermal growth factor receptor, mucin-7, tenascin-C, survivin and human telomerase reverse transcriptase are detectable at the mRNA level in the blood cellular fraction of UC patients, yet their clinical significance has not been clarified \[[@ref005]\]. Among the available methods, that were reviewed in a  meta-analysis from 21 studies on more than 800 patients \[[@ref012]\], CTC isolation using the CellSearch^®^ assay (Janssen Diagnostics, Raritan, NJ) proved to be associated with metastatic tumor load \[[@ref013]\], and provided clinically relevant results, particularly in patients with early stage disease \[[@ref017]\]. Conversely, there is limited information regarding the role of CTCs in monitoring response and outcome of chemotherapy in patients with high-grade or advanced disease \[[@ref017]\]. Moreover, methods based on EpCAM-dependent enrichment usually fail to enrich for CTCs with mesenchymal features, suggesting that implementation of capture systems with additional antibodies is required, and analysis of more than one molecular marker at the transcript level may increase the detection capability \[[@ref024]\].

Here we report a single-center, prospective study on a population of UC patients receiving first-line chemotherapy for metastatic disease. In consideration of the small sample size it represents a pilot study aiming at evaluate the clinical validity of early CTC monitoring by using an original immunomagnetic- and PCR-based CTC detection approach in the metastatic context. Clinical validity of our CTC assay, which represents the primary objective of this study, was mainly investigated in terms of association with progression-free survival (PFS) and overallsurvival (OS).

PATIENTS AND METHODS {#sec0010}
====================

Study design {#sec0015}
------------

From July 2012 to May 2014, 31 patients received first-line methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy for metastatic disease at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. A flow chart including reason for patient exclusion is shown in [Fig. 1](#blc-2-blc160069-g001){ref-type="fig"}. Blood aliquots were collected at baseline (i.e., at T~0~, the day before starting chemotherapy) and after the second cycle (at T~2~) together with the disease restaging as per Institutional policy. The second disease assessment was planned at the end of treatment (4 to 6 cycles of chemotherapy). Responses were assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 \[[@ref025]\]. Close surveillance was applied in all cases who achieved at least a stable disease (SD), and computed tomography scans were repeated every 3 months in this phase.

The study was carried out after approval of the Institutional Review Board and Ethical Committee and written informed consent was obtained from all patients.

Method of CTC assessment {#sec0020}
------------------------

Samples of peripheral whole blood were collected in K~3~EDTA BD Vacutainer tubes. CTC analysis was performed on an 8 mL sample obtained after withdrawal of the blood volumes (about 50 mL) necessary for routine tests minimizing this way the risk of contamination with epithelial skin cells during puncture. Following the reporting recommendations for tumor marker prognostic studies (REMARK) \[[@ref026]\], fresh samples were stored at 4°C at dark and processed within 1 hour from withdrawal. Enrichment for CTCs was performed using the AdnaTest ProstateCancerSelect kit (AdnaGen, AG, Langenhagen, Germany). Briefly, 5 mL of whole blood were incubated with 100 μL of magnetic beads coated with antibodies against the epithelial and tumor-associated antigens EpCAM and ErbB2. Cell-beads complexes were captured using the AdnaMag-L magnetic particle concentrator and cell lysates were stored at --20 °C for up to 14 days before mRNA isolation and molecular analysis (AdnaTest BreastCancerDetect kit,AdnaGen).

The expression of *EPCAM*, *MUC1* and *ERBB2* epithelial and tumor-specific markers, co-amplified with *ACTB* as control, was assessed by semiquantitative multiplex-PCR using the PrimerMix provided in the AdnaTest BreastCancerDetect kit.

The following values were used for each single gene: ≥0.40 ng/μL for EPCAM, ≥0.10 ng/μL for MUC1 and ≥0.20 ng/μL for ERBB2. Samples were called as CTC-positive if at least one of either EPCAM, MUC1 or ERBB2 marker level was above the cut-off value. Otherwise, they were defined as CTC-negative.

For quality control assessment, *ACTB* concentration≥3.0 ng/μL was established as a necessary criterion to consider a CTC sample as evaluable, on the basis of results obtained from healthy donors. Results from CTC test were collected and analyzed without knowledge of clinical data.

Statistical analyses {#sec0025}
--------------------

Patient, disease features, and outcome data were summarized using descriptive statistics with frequencies and percentages used for categorical variables and medians and inter-quartile range (IQR) forcontinuous variables. The associations between variables were assessed by Fisher and *χ*^2^ tests, with Yates' correction when appropriate. The primary objective of the analysis was to evaluate the prognostic role of either T~0~, T~2~, or T~0~-T~2~ CTC status and variation on PFS and OS. As this study was exploratory in nature, no formal statistical hypothesis was postulated, although the enrolled number of patients was consistent with the entropy-based approach to sample size in translational clinical trials as proposed by Piantadosi et al. \[[@ref027]\]. Two-year minimum follow-up was allowed to have reliable survival data. Based on the hypothesis that CTC changes could better predict the outcome, samples were grouped according to CTC variation. Additionally, due to small numbers, CTC variation was arbitrarily split in favorable (--/--, +/--and --/+) and unfavorable (+/+) groups using the positivity cut-offs and positivity criteria already described.

The Kaplan-Meier method was used for estimation of time-to-event outcomes such as PFS and OS. Cox proportional hazards regression was used to investigate the prognostic role of CTC status and variations, and of the other clinical-pathologic factors on PFS and OS, with relative hazard ratios (HR) and 95% confidence intervals (CI), using the putative best prognosis category as a reference. Each selected factor was investigated in univariable analyses. Due to small numbers, bivariable analyses were performed to evaluate the independent prognostic impact of CTC trend after controlling for the following clinical factors: presence *vs.* absence of liver metastases, MSKCC score (1-2 *vs.* 0) \[[@ref028]\], and RECIST response (progressive disease \[PD\] *vs.* complete response \[CR\]+partial response \[PR\]+SD). All tests (performed in SAS software, version 9.2) were two-sided and a *p*-value of≤0.05 was considered statistically significant.

RESULTS {#sec0030}
=======

Patient characteristics {#sec0035}
-----------------------

[Table 1](#blc-2-blc160069-t001){ref-type="table"} presents patient and tumor baseline characteristics. Median follow-up for censored patients was 27 months (IQR 12--35). Overall, median PFS and OS were 8 months (IQR 5--22) and 12 months (IQR 8--27), respectively. Twenty-one patients progressed and 16 died for disease progression after 3 years of follow-up.

At T~0~ 17/31 (54.8%) patients were CTC-positive. No clinical or histopathological characteristics were associated with baseline CTC status ([Table 1](#blc-2-blc160069-t001){ref-type="table"}). CTC positivity at T~2~ was obtained in 17/26 (65.4%) evaluable patients. *MUC1* was the most frequently detected marker among CTC-positive samples both at T~0~ (76.5%) and at T~2~ (88.2%), whereas *EPCAM* contribute to CTC positivity was 64.7% at T~0~ and 70.6% at T~2~. Co-expression of *EPCAM* and *MUC1* was observed in 17.6% and 58.8% of CTC-positive samples at T~0~ and T~2~, respectively, while *ERBB2* was detected in 41.2% of CTC-positive samples at T~0~ and never at T~2~. Baseline co-expression of the three investigated markers was found in 29.4% of CTC-positive samples ([Supplementary Table 1](#S1){ref-type="supplementary-material"}).

Association of CTC status and CTC changes with response and outcome {#sec0040}
-------------------------------------------------------------------

CTC status, evaluated at T~0~ or T~2~ time-points or as CTC trend (defined as CTC status variation between T~0~ and T~2~ and categorized as --/--, +/-- and --/+ *vs.* +/+), was not significantly associated with RECIST response, either categorized as CR+PR+SD *vs.* PD, CR *vs.* PR+SD *vs.* PD or CR+PR *vs.* SD+PD.

Results of univariable analyses of 3-year PFS and OS are shown in [Table 2](#blc-2-blc160069-t002){ref-type="table"}. Presence of liver metastases, MSKCC score, and clinical response were significantly associated to PFS and OS. PFS and OS were higher in CTC-positive patients, both at T~0~ and at T~1,~ compared to CTC-negative ones (T~0~: 50.0% vs. 17.6%, T~2~: 44.4% vs. 29.4% and T~0~: 57.1% vs. 28.8%, T~2~: 59.3% vs. 41.2%, for PFS and OS, respectively). However, categorization of patients according to CTC evaluated at T~0~ and T~2~ was not prognostic, whereas an association with PFS (HR: 5.04, 95% CI: 1.58--16.05, *p* = 0.006, [Fig. 2A](#blc-2-blc160069-g002){ref-type="fig"}) and OS (HR: 3.97, 95% CI: 1.27--12.38, *p* = 0.017, [Fig. 2B](#blc-2-blc160069-g002){ref-type="fig"}) was observed after splitting patients according to CTC trend. In patients with persistent CTC-positive status (unfavorable CTC trend) the median PFS was 6 months, remarkably shorter compared to patients with favorable CTC trend (20 months). Median OS of the former was 8 months whereas more than 65% of patients with favorable CTC was alive at 3 years. In addition, PFS and OS were analyzed as a function of CTC trend in the response subsets ([Supplementary Table 2](#S2){ref-type="supplementary-material"}). Patients with CR to chemotherapy showed higher PFS and OS probabilities in the group with favorable CTC trend compared to the unfavorable one (100% *vs*. 33%, respectively, for both PFS and OS), while those with PR or SD had shorter PFS when CTC status was persistently positive compared to cases with favorable trend (42% *vs*. 0%, *p* = 0.023).

Results of Cox bivariable analyses are shown in [Table 3](#blc-2-blc160069-t003){ref-type="table"}. CTC trend was still prognostic for PFS and OS after adjusting for liver metastases (*p*-value* = *0.0314 and 0.0255, respectively) and MSKCC score (*p*-value = 0.014 and 0.025, respectively). After controlling for response, CTC trend was prognostic for PFS (HR: 2.95, 95% CI: 1.02--8.56, *p* = 0.046) but not for OS (HR: 2.84, 95% CI: 0.80--10.07, *p* = 0.106). On the other side, adjustment for CTC trend maintained the statistical significance of MSKCC (HR: 3.19; 95% CI: 1.12--9.10; *p* = 0.031) and response (HR: 47.47; 95% CI: 3.77--597.85; *p* = 0.003) on PFS, whereas the prognostic significance on OS was maintained as a trend for MSKCC only (HR: 3.20; 95% CI: 1.00--10.28; *p* = 0.051).

DISCUSSION {#sec0045}
==========

The present pilot study was designed to evaluate the feasibility of an immunoenrichment method for CTC detection, adapted for UC patients, at our laboratory. Despite the limited sample size, we were able to find an association between patient outcomes and CTC changes early during first-line MVAC chemotherapy. Indeed an unfavorable CTC trend not only identified patients with a remarkably short PFS and OS, but also resulted to add information to well-established prognostic factors. Our results represent therefore a first step toward clinical validation, despite many possible limitations.

Being a pilot study in nature, the number of enrolled patients prevented us from better stratifyingpatients according to CTC trend. Whereas the allocation in the unfavorable group of patients with persistently CTC positive blood samples between T~0~ and T~2~ is straightforward, inclusion of patients with negative baseline CTC and positive CTCs at T~2~ in the favorable group could appear counterintuitive. However, considering that at T~2~ almost two thirds of patients were defined as CTC positive, a  possible interference of treatment on CTC release cannot be ruled out. In a recent publication, Martin et al. \[[@ref029]\] reviewed clinical data suggesting that, although in general high numbers of CTCs are associated with bad prognosis, mobilization of CTC induced by treatment is possible and not necessarily associated with an adverse effect. For such a reason, patients who were defined as CTC-negative at baseline, but who switched to positive CTC, were included in the favorable group. Only the analysis of a higher number of patients will allow understanding if such speculation is correct; alternatively in the future the CTC assay could be modified to include a biomarker for apoptosis similarly to what has been done with the CellSearch^®^ approach in other tumor types \[[@ref030]\].

Some other important limitations should be acknowledged in the present study. First, the small number of patients might have affected the reliability of regression analyses, and for this reason we evaluated the contribution of CTC trend to clinical outcomes adjusted for one clinical factor each time. Second, it is possible that the bivariate model did not account for inherent selection biases resulting from the long period of enrollment. However, although patient characteristics were consistent with those of first-line metastatic patients, almost all MVAC-treated patients at our center were included (only 12 patients who received 1 cycle only due to the development of intolerable side effects were excluded) and the chemotherapy regimen was homogeneous as already reported \[[@ref032]\]. Furthermore, quality indicators of the present cohort were the detrimental prognostic significance of liver metastases, MSKCC score and RECIST response. Third, given the exploratory nature of our study, which represents a pilot study exploiting the feasibility of an alternative CTC detection method for predicting clinical outcome, a generalization of results is impossible thus far.

In general, the identification of novel and validated prognostic factors in metastatic UC patients, mainly if they can be used early in the treatment course, is of paramount importance both in the daily practice and in the context of clinical trials. In daily clinical practice, based on the recent developments of immunotherapy in the salvage setting, new active drugs may be offered to those patients for whom a biomarker is able to predict chemoresistance or poor prognosis early after initiation of conventional therapy, whereas in a clinical trial new drugs or combination therapies can be investigated after few cycles of standard chemotherapy focusing on poor prognosis patients.

A similar objective did characterize another study that was conducted at our center with the use of early ^18^fluorodeoxyglucose (FDG) positron emission tomography after 2 cycles of first-line cisplatin-based chemotherapy (PET-2) in patients with metastatic UC. In 31 eligible patients, early variations in tumor FDG avidity at PET-2 were independently associated with PFS but not with OS \[[@ref033]\]. Thus it is possible to hypothesize that the analysis of early CTC changes might result in enhancing imaging assessments and early predicting the outcome of patients, but this is presently only a hypothesis which deserves confirmation.

Most studies addressing CTC as potential biomarker in UC have used the CellSearch^®^ platform \[[@ref012]\], which has been approved by the FDA only for guiding treatment in metastatic breast, prostate and colon cancer. Different technical approaches like ours have been limitedly used. A recent study, which employed the IsoFlux test in comparison to CellSearch^®^ in the neoadjuvant and metastatic settings \[[@ref023]\] reported that baseline CTC levels were better predictors of pathologic stage compared to CTC evaluated after one cycle of chemotherapy. The dynamic evaluation of CTC was not reported and a direct comparison with our data is prevented by the absence of clinical outcome data in the metastatic setting. Interestingly, the study by Alva et al. \[[@ref023]\] reports preliminary data on the possibility to perform a sensitive next generation sequencing on CTCs which might detect clinically useful genomicalterations.

Indeed, for an effective translational research, CTC molecular characterization as well as circulating cell-free DNA may be ideal tools to non-invasively identify potentially "actionable" tumor alterations, ultimately leading to expedite precision therapy in "basket" and "umbrella" studies. Preliminary findings from such studies have been recently provided, showing that molecular analyses may be also useful in monitoring the tumor burden during treatment \[[@ref034]\]. Of course, relevant pending issues are represented by the comparison of molecular profiling of CTCs or cell-free tumor DNA from liquid biopsies with that obtained from the primary tumor, the dynamic changes of such molecular alterations, hopefully able to capture information on disease evolution, and the development of reliable and robust molecular diagnostic and predictive tools. CTCs, as well as other components of liquid biopsies, have the potential to provide extraordinary information to improve patient'smanagement.

The rarity of CTCs and their marked plasticity pose technical difficulties that still limit their clinical validity. Compared to classical EpCAM-based CTC enrichments methods \[[@ref012]\] our approach presents the advantage of capturing also those CTCs which do not express epithelial antigens, thanks to the binding of an anti ERBB2 antibody linked the immunomagnetic beads used for CTC-enrichments, and of identifying CTCs not strictly based on their expression of epithelial genes only. In other clinical settings this strategy contributed to increase CTC positivity \[[@ref024]\], but in UC no direct evidences are available since matched methodological comparisons were not performed on the same samples.

In conclusion, we propose an original method of assessing positivity and analyzing changes of CTC in patients with metastatic UC receiving first-line MVAC chemotherapy. Our study showed a significant association of CTC changes with clinical outcome; in particular, patients with persistently positive CTC after 2 cycles of MVAC had significantly worse PFS and OS. Pending validation of reproducibility and reliability of CTC results, as well as the clinical validity of such an association compared to standard radiologic assessments, these findings might help physicians improving patient prognostication, optimizing the administration of standard chemotherapy options, and designing clinical trials of sequential first-line therapies.
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Three-year progression-free and overall survival probabilities according to CTC trend, stratified by objective response to chemotherapy.
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![Study flow chart, with counts and reasons for patient selection. Abbreviations: MVAC: methotrexate, vinblastine, doxorubicin, cisplatin chemotherapy; UC: urothelial carcinoma.](blc-2-blc160069-g001){#blc-2-blc160069-g001}

![Kaplan-Meier curves of progression-free (A) and overall survival (B) according to CTC trend after the first 2 cycles of chemotherapy. *Legend*: light grey line: favorable CTC trend; dark grey line: unfavorable CTC trend. Abbreviations: CTC: circulating tumor cells; HR: hazard ratio; CI: confidence interval; OS: overall survival; PFS: progression-free survival.](blc-2-blc160069-g002){#blc-2-blc160069-g002}

###### 

Patient and tumor characteristics at baseline

  Variable                 No of   No of CTC+    *p*-value
  ----------------------- ------- ------------ -------------
  All patients              31     17 (54.8)   
  Gender                                       
    Female                   9      5 (55.6)    *1.0^*a*^*
    Male                    22     12 (54.5)   
  Age                                          
    \<65                    13      5 (38.5)    *0.23^*b*^*
    ≥65                     18     12 (66.7)   
  Tumor primary site^‡^                        
    Bladder                 26     13 (50.0)    *0.35^*a*^*
    Upper tract              5      4 (80.0)   
  Metastatic sites                             
    Lymph-nodes             21     12 (57.1)    *0.21^*c*^*
    Liver-Lung-Bone         17     11 (64.7)   
    Other^\*^                5      1 (20.0)   
  Histology                                    
    Pure UC                 24     14 (58.3)    *0.47^*c*^*
    Other                    7      3 (42.9)   
  Smoking status^§^                            
    Never smoker             9      3 (33.3)    *0.11^*d*^*
    Former smoker           11      5 (45.5)   
    Current smoker           9      7 (77.8)   
  MSKCC score                                  
    0                       15      7 (46.7)    *0.38^*e*^*
    1                       10      6 (60.0)   
    2                        6      4 (66.7)   

Abbreviations: CTC: circulating tumor cell; UC: urothelial carcinoma. ^‡^One patient had disease in both sites. ^\*^Peritoneum, soft tissue, pleura, brain. ^§^The analyses involved 29/31 patients as data were missing. ^a^Fisher's exact test. ^b^Chi-square test with Yates' correction. ^c^Chi-square test. ^d^Fisher's exact test, Never+Former smokers *vs.* Current smokers. ^e^Chi-square test, 0 vs. 1 + 2

###### 

Univariable analyses of 3-year progression-free and overall survival

  Variable                   N    PFS             OS                                                  
  ------------------------- ---- ------ ---------------------- ---------- ------ -------------------- ---------
  CTC status at T~0~                                                                                  
    Negative^\*^             14   50.0                                     57.1                       
    Positive                 17   17.6    1.87 (0.75--4.65)      *0.18*    28.8   1.72 (0.62--4.74)    *0.30*
  CTC status at T~2~                                                                                  
    Negative^\*^             9    44.4                                     59.3                       
    Positive                 17   29.4    1.75 (0.61--4.92)      *0.31*    41.2   2.03 (0.56--7.44)    *0.28*
  CTC variation T~0~-T~2~                                                                             
    Negative-negative^\*^    4    50.0            --               --      50.0           --             --
    Positive-negative        5    40.0    0.99 (0.17--5.94)      *0.99*    66.7   0.41 (0.037--4.55)   *0.47*
    Negative--positive       7    57.1    0.80 (0.13--4.82)      *0.81*    71.4   0.52 (0.074--3.73)   *0.52*
    Positive-positive        10   10.0    2.85 (0.61--13.37)     *0.18*    20.0   2.41 (0.50--11.52)   *0.27*
  Liver metastases                                                                                    
    Negative^\*^             26   37.6                                     46.4                       
    Positive                 5     0      3.37 (1.19--9.56)     *0.022*    26.7   4.62 (1.13--18.95)   *0.033*
  MSKCC score                                                                                         
    0^\*^                    15   45.7                                     57.1                       
    1 + 2                    16   18.7    2.55 (1.04--6.27)     *0.040*    26.5   2.88 (1.03--8.14)    *0.045*
  RECIST response                                                                                     
    CR+PR+SD^\*^             22   35.8                                     49.4                       
    PD                       5     0     55.27 (6.06--504.37)   *0.0004*    0     5.30 (1.57--17.92)   *0.007*

Abbreviations: CI: confidence interval; CR: complete response; CTC: circulating tumor cell; HR: hazard ratio; OS: overall survival; PD: progressive disease; PFS: progression-free survival; PR: partial response; RECIST: Response Evaluation Criteria in Solid Tumors; SD: stable disease. ^\*^Reference category.

###### 

Bivariable analysis of 3-year progression-free and overall survival as a function of CTC trend

  Variable        Progression-Free Survival   Overall Survival                                                                                                 
  -------------- --------------------------- ------------------ ---------- ------ ------------ ---------- ------ ------------- ---------- ------ ------------- ----------
  Liver                     2.01                 0.54--7.40      *0.2967*   2.95   1.01--7.89   *0.0314*   4.10   0.71--23.76   *0.1156*   3.71   1.17--11.71   *0.0255*
    metastases                                                                                                                                                 
  MSKCC                     3.19                 1.12--9.10      *0.0306*   3.56   1.29--9.81   *0.0140*   3.20   1.00--10.28   *0.0509*   3.75   1.17--11.97   *0.0255*
    score                                                                                                                                                      
  RECIST                    47.47               3.77--597.85     *0.0028*   2.95   1.02--8.56   *0.0464*   2.17   0.42--11.28   *0.3590*   2.84   0.80--10.07   *0.1057*
    response                                                                                                                                                   

Abbreviations: CI: confidence interval; CTC: circulating tumor cell; HR: hazard ratio; RECIST: Response Evaluation Criteria in Solid Tumors. ^\*^Split in favorable (--/--, +/--and --/+) and unfavorable (+/+) groups based on T~0~ and T~2~ assessments.
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